



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:413

May 24, 2013

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Audited Financial Results for the year ended on March 31, 2013.

Enclosed please find the audited financial results of the company for the year ended on March 31, 2013. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,


M. C. Mehta
Company Secretary – General Manager

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200


FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

STATEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31/03/2013

Sl. No.	PART I - Particulars	Quarter ended			Year ended		Consolidated year ended	
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	31/03/2013	31/03/2012
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Income from Operations							
	a. Net sales (Net of excise duty)	19,772.75	19,976.13	14,800.02	79,446.05	63,577.48	84,575.84	77,619.17
	b. Other Operating Income	741.59	453.10	678.13	2,196.20	5,064.65	2,036.72	2,567.67
	Total Income from Operations (Net) (a+b)	20,514.34	20,429.23	15,478.15	81,642.25	68,642.13	86,612.56	80,186.84
2	Expenses							
	a. Cost of materials consumed	6,210.78	6,509.73	4,615.28	26,190.38	20,320.53	26,189.51	20,320.53
	b. Purchases of stock-in-trade	2,099.38	1,947.23	2,896.89	7,155.17	6,999.76	10,688.67	9,996.17
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(101.12)	11.44	(1,709.68)	480.97	(547.18)	(31.69)	1,322.92
	d. Employees benefits expense	3,134.89	2,905.61	2,632.17	12,012.87	10,131.32	13,004.53	11,266.33
	e. Depreciation and amortization expense	600.58	625.00	532.46	2,439.58	2,230.40	2,465.82	2,242.46
	f. Exchange Fluctuation Transactional (Gain)/Loss	(88.82)	638.87	1,281.26	1,582.58	1,736.63	1,505.84	1,578.86
	g. Other Expenses	6,528.47	5,855.38	7,380.78	23,746.56	22,263.00	25,332.85	24,375.72
	Total Expenses	18,384.16	18,493.26	17,629.16	73,608.11	63,134.46	79,155.53	71,102.99
3	Profit/(Loss) from Operations before Other Income, Finance Cost and exceptional item (1-2)	2,130.18	1,935.97	(2,151.01)	8,034.14	5,507.67	7,457.03	9,083.85
4	Other Income	256.77	780.89	445.62	2,596.07	2,851.19	2,787.26	2,898.34
5	Profit/(Loss) from Ordinary Activities before Finance Cost and exceptional item (3+4)	2,386.95	2,636.86	(1,705.39)	10,630.21	8,358.86	10,244.29	11,982.19
6	Finance Cost	116.42	187.97	243.18	524.18	2,177.69	528.86	2,402.81
7	Profit/(Loss) from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	2,270.53	2,448.89	(1,948.57)	10,106.03	6,181.17	9,716.23	9,579.38
8	Exchange Fluctuation Translation Gain / (Loss)	12.80	674.86	2,748.20	668.44	(1,318.27)	641.26	(1,294.51)
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+8)	2,283.33	3,123.75	799.63	10,774.47	4,862.90	10,357.49	8,284.07
10	Exceptional item	-	-	-	-	76,059.34	-	76,059.34
11	Profit from Ordinary Activities before Tax (9+10)	2,283.33	3,123.75	799.63	10,774.47	80,922.24	10,357.49	84,344.21
12	Tax expenses	308.10	936.35	(86.93)	2,280.62	16,652.30	2,413.08	16,553.33
13	Net Profit for the period from Ordinary Activities after Tax (11-12)	1,975.23	2,187.40	886.56	8,493.85	64,269.94	7,944.41	67,790.88
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.15	1,694.15	1,694.15	1,694.15	1,694.15	1,694.15	1,694.15
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	99,206.03	93,692.17	100,332.97	95,301.14
16	Earning per share (EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	2.33	2.58	1.05	10.03	75.95	9.38	80.11
	(2) Diluted	2.33	2.58	1.05	10.03	75.95	9.38	80.11

Sl. No.	PART II - Particulars	Quarter ended			Year ended	
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012
		Audited	Unaudited	Audited	Audited	Audited
A	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					
	- Number of Shares	37,381,103	37,381,103	37,380,603	37,381,103	37,380,603
	- Percentage of shareholding	44.13	44.13	44.13	44.13	44.13
2	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered	-	-	-	-	-
	- Number of Shares	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-
	a) Pledged/Encumbered	-	-	-	-	-
	b) Non-encumbered					
	- Number of Shares	47,326,197	47,326,197	47,326,697	47,326,197	47,326,697
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	180.80	100.00	180.00	100.80	180.80
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.87	55.87	55.87	55.87



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

B INVESTOR COMPLAINTS

Particulars	3 Months ended 31/03/2013
Pending at the beginning of the quarter	Nil
Received during the quarter	5
Disposed of during the quarter	5
Remaining unresolved at the end of the quarter	Nil

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on May 24, 2013.
- The other operating income for the year ended March 2012 included dividend of Rs.24.97 crores received from the company's Russian Subsidiary.
- The figures for the year ended on March 31, 2013 are strictly not comparable with the previous year consequent to sale of Russia-CIS OTC business undertaking on July 14, 2011.
- The board of directors has recommended dividend of Rs.3 (150%) per equity share of face value of Rs.2. This together with dividend distribution tax will absorb Rs.2,973.10 lakhs.
- The figures for the quarter ended on March 31, 2013 are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter ended on December 31, 2012.
- The company is engaged in a single segment of activity namely, "Pharmaceuticals".
- Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2013 is as under:

STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(₹ in Lakhs)

	Particulars	Standalone		Consolidated	
		AS AT 31/03/2013	AS AT 31/03/2012	AS AT 31/03/2013	AS AT 31/03/2012
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
a.	Share Capital	1,694.15	1,694.15	1,694.15	1,694.15
b.	Reserves and surplus	99,206.03	93,692.17	100,332.97	95,301.14
	Sub Total of Shareholders' funds	100,900.18	95,386.32	102,027.12	96,995.29
2	Non-current liabilities				
a.	Long-term borrowings	724.26	1,152.17	774.71	1,254.50
b.	Deferred tax liabilities (Net)	2,197.49	1,655.69	2,498.03	1,871.04
c.	Long-term provisions	822.82	826.84	822.82	826.84
	Sub-Total - Non-current liabilities	3,744.57	3,634.70	4,095.56	3,952.38
3	Current liabilities				
a.	Short-term borrowings	3,677.35	5,522.65	3,677.35	5,522.65
b.	Trade payables	5,176.14	3,353.77	6,050.76	3,709.02
c.	Other current liabilities	9,840.87	7,669.74	10,115.39	7,874.96
d.	Short-term provisions	3,943.30	1,704.53	4,053.82	1,725.59
	Sub-Total - Current liabilities	22,637.66	18,250.69	23,897.32	18,832.22
	TOTAL-EQUITY AND LIABILITIES	127,282.41	117,271.71	130,020.00	119,779.89
B	ASSETS				
1	Non-current assets				
a.	Fixed assets	29,917.34	28,000.53	32,231.31	29,840.78
b.	Goodwill on consolidation	-	-	1,690.23	1,690.23
c.	Non-current investments	3,897.98	3,878.98	299.31	299.61
d.	Long-term loans and advances	1,428.47	1,258.29	1,428.47	1,327.37
e.	Other non-current assets	-	-	-	-
	Sub-Total - Non-current assets	35,243.79	33,137.80	35,649.32	33,157.99
2	Current assets				
a.	Current investments	39,467.80	29,892.18	39,467.80	29,892.18
b.	Inventories	8,988.92	9,079.85	10,453.49	10,103.24
c.	Trade receivables	19,464.31	13,120.82	19,127.39	13,605.11
d.	Cash and cash equivalents	14,910.99	21,136.24	15,623.49	21,953.25
e.	Short-term loans and advances	9,206.60	10,904.82	9,698.52	11,068.12
	Sub-Total - Current assets	92,038.62	84,133.91	94,370.68	86,621.90
	Total-Assets	127,282.41	117,271.71	130,020.00	119,779.89

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : May 24, 2013

J.B.Mody
Chairman & Managing Director